Clinical manifestations and management of antiretroviral nucleoside analog: Related mitochondrial toxicityMOYLE, G.Clinical therapeutics. 2000, Vol 22, Num 8, pp 911-936, issn 0149-2918Article

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequencesMOYLE, G. J.Drugs (Basel). 1996, Vol 52, Num 2, pp 168-185, issn 0012-6667Article

Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy : the potential to use resistance data to guide clinical decisionsMOYLE, G. J.Journal of antimicrobial chemotherapy (Print). 1997, Vol 40, Num 6, pp 765-777, issn 0305-7453Article

Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and managementMOYLE, G. J; SADLER, M.Drug safety. 1998, Vol 19, Num 6, pp 481-494, issn 0114-5916Article

Once-daily therapy: less is moreMOYLE, G.International journal of STD & AIDS. 2003, Vol 14, pp 1-5, issn 0956-4624, 5 p., SUP1Conference Paper

The development of resistance of HIV-1 to zalcitabineCRAIG, C; MOYLE, G.AIDS (London). 1997, Vol 11, Num 3, pp 271-279, issn 0269-9370Article

Current knowledge and future prospects for the use of HIV protease inhibitorsMOYLE, G; GAZZARD, B.Drugs (Basel). 1996, Vol 51, Num 5, pp 701-712, issn 0012-6667Article

Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected SubjectsSINGH, K; DICKINSON, L; BOFFITO, M et al.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 6, pp 867-872, issn 0009-9236, 6 p.Article

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsGAZZARD, B; MOYLE, G.Lancet (British edition). 1998, Vol 352, Num 9124, pp 314-316, issn 0140-6736Article

Occurrence of an environmental estrogen (4-nonylphenol) in sewage treatment plant effluent and the aquatic receiving environmentSEKELA, M; BREWER, R; MOYLE, G et al.Water science and technology. 1999, pp 217-220, issn 0273-1223, isbn 0-08-042818-5Conference Paper

Progressive CD4 cell depletion and death in zidovudine-treated patientsEASTERBROOK, P. J; JAVAD EMAMI; MOYLE, G et al.Journal of acquired immune deficiency syndromes. 1993, Vol 6, Num 8, pp 927-929, issn 0894-9255Article

Gonococcal arthritis caused by auxotype P in a man with HIV infectionMOYLE, G; BARTON, S. E; MIDGLEY, J et al.Genitourinary medicine. 1990, Vol 66, Num 2, pp 91-92, issn 0266-4348, 2 p.Article

Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapyBALL, J. K; ROWE, T; CURRAN, R et al.Sexually transmitted infections. 1999, Vol 75, Num 5, pp 337-339, issn 1368-4973Article

Foscarnet and ganciclovir in the treatment of CMV retinitis in AIDS patients : a randomised comparisonMOYLE, G; HARMAN, G; MITCHELL, S et al.The Journal of infection. 1992, Vol 25, Num 1, pp 21-27, issn 0163-4453Article

The Assessing Patients' Preferred Treatments (APPT-1) studyMOYLE, G.International journal of STD & AIDS. 2003, Vol 14, pp 34-36, issn 0956-4624, 3 p., SUP1Conference Paper

The SPICE study : 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analoguesMOYLE, G; POZNIAK, A; SALGO, M et al.Journal of acquired immune deficiency syndromes (1999). 2000, Vol 23, Num 2, pp 128-137, issn 1525-4135Article

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeterREVICKI, D. A; MOYLE, G; STELLBRINK, H.-J et al.AIDS (London). 1999, Vol 13, Num 7, pp 851-858, issn 0269-9370Article

Loss of the CD56^hiCD16^- NK cell subset and NK cell interferon-γ production during antiretroviral therapy for HIV-1: partial recovery by human growth hormoneGOODIER, M. R; IMAMI, N; MOYLE, G et al.Clinical and experimental immunology (Print). 2003, Vol 134, Num 3, pp 470-476, issn 0009-9104, 7 p.Article

Antiretroviral therapy for HIV-2 infected patientsSMITH, N. A; SHAW, T; FAKOYA, A et al.The Journal of infection. 2001, Vol 42, Num 2, pp 126-133, issn 0163-4453Article

Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European Expanded Access ProgrammeMOYLE, G; GOLL, A; SNAPE, S et al.International journal of antimicrobial agents. 1996, Vol 7, Num 1, pp 41-48, issn 0924-8579Article

Surrogate markers now provide physicians with the best means to manage antiretroviral therapy : The case forMOYLE, G. J; GAZZARD, B. G.Genitourinary medicine. 1997, Vol 73, Num 3, pp 216-218, issn 0266-4348Article

A risk-benefit assessment of HIV protease inhibitorsMOYLE, G. J; GAZZARD, B. G.Drug safety. 1999, Vol 20, Num 4, pp 299-321, issn 0114-5916Article

Individualisation of HIV therapy : the clinician's perspectiveGAZZARD, B. G; MOYLE, G. J.British journal of clinical practice. 1995, Vol 49, Num 3, pp 145-147, issn 0007-0947Article

HIV-proteinase inhibitors in the management of HIV-infectionMOYLE, G. J; BARTON, S. E.Journal of antimicrobial chemotherapy (Print). 1996, Vol 38, Num 6, pp 921-925, issn 0305-7453Article

Frequency of multinucleoside analogue-resistant genotypes observed during antiretroviral therapyMOYLE, G. J; BASAR, A; GAZZARD, B. G et al.AIDS (London). 2000, Vol 14, Num 9, pp 1292-1293, issn 0269-9370Article